Id |
Subject |
Object |
Predicate |
Lexical cue |
T134 |
0-4 |
Sentence |
denotes |
2.2. |
T135 |
6-67 |
Sentence |
denotes |
Prediction of activity spectra for substances (PASS) analysis |
T136 |
68-158 |
Sentence |
denotes |
PASS is an online web tool hosted at http://195.178.207.233/PASS/index.html (Ahmad, 2019). |
T137 |
159-308 |
Sentence |
denotes |
Based on the structure–activity relationship with a known chemical entity, PASS analysis server predicts biological activities of chemical compounds. |
T138 |
309-467 |
Sentence |
denotes |
The tool predicts the pharmacological behavior, mechanism of action and side effects such as mutagenicity, carcinogenicity, embryotoxicity and teratogenicity. |
T139 |
468-622 |
Sentence |
denotes |
In the present study, PASS analysis was performed using OSIRIS Property Explorer version 4.5.1. (http://www.openmolecules.org/propertyexplorer/index.html) |
T140 |
624-630 |
Sentence |
denotes |
2.2.1. |
T141 |
632-655 |
Sentence |
denotes |
Lipinski’s rule of five |
T142 |
656-808 |
Sentence |
denotes |
The druglikeness of WS phytoconstituents was also assessed using Lipinski’s rule of five (Ertl et al., 2000; Lipinski et al., 1997; Veber et al., 2002). |
T143 |
809-1052 |
Sentence |
denotes |
The parameters of druglikeness such as MW ≤500, logP ≤5, number of hydrogen bond donors (NOHNH) ≤5 and hydrogen bond acceptor sites (NON)≤10, topological polar surface area (TPSA) (≤140 Å2), and number of rotatable bonds (≤10) were determined. |
T144 |
1053-1259 |
Sentence |
denotes |
In the present study, the druglikeness of selected WS phytoconstituents was analyzed using Molinspiration (http://www.molinspiration.com/cgi-bin/properties) and compared to that of standard reference drugs. |
T145 |
1261-1267 |
Sentence |
denotes |
2.2.2. |
T146 |
1269-1279 |
Sentence |
denotes |
Veber rule |
T147 |
1280-1351 |
Sentence |
denotes |
For oral bioavailability, membrane permeability is an important factor. |
T148 |
1352-1488 |
Sentence |
denotes |
Polar surface area and number of rotatable bonds are two critical considerations for a compound to behave as a potential drug candidate. |
T149 |
1489-1657 |
Sentence |
denotes |
With a reduction in polar surface area, permeation increases and with the increase in number of rotatable bonds permeation decreases significantly (Veber et al., 2002). |
T150 |
1658-1778 |
Sentence |
denotes |
The following two criteria should be met by a potential drug candidate in order to obey Veber rules:≤10 rotatable bonds; |
T151 |
1779-1850 |
Sentence |
denotes |
Polar surface area ≤140Å2 (or 12 or fewer H-bond donors and acceptors). |
T152 |
1852-1858 |
Sentence |
denotes |
2.2.3. |
T153 |
1860-1872 |
Sentence |
denotes |
Ghose filter |
T154 |
1873-2018 |
Sentence |
denotes |
Receptor binding, cellular uptake and bioavailability of drug molecules is strongly influenced by molecular lipophilicity and molar refractivity. |
T155 |
2019-2269 |
Sentence |
denotes |
Both of them signify hydrophobic and dispersive (van der Waals) interactions (Ghose & Crippen, 1987) of a drug molecule and are employed in 3D-QSAR studies to evaluate the drug-like character of molecules under study (Viswanadhan et al., 1990, 1991). |
T156 |
2270-2428 |
Sentence |
denotes |
The following are the qualifying parameters for a putative drug candidate as per Ghose filter:clogP range between -0.4 and 5.6, with an average value of 2.52; |
T157 |
2429-2488 |
Sentence |
denotes |
MW range between 160 and 480, with an average value of 357; |
T158 |
2489-2562 |
Sentence |
denotes |
Molar refractivity range between 40 and 130, with an average value of 97; |
T159 |
2563-2632 |
Sentence |
denotes |
Total number of atoms between 20 and 70, with an average value of 48. |
T160 |
2633-2805 |
Sentence |
denotes |
The above parameters should be kept in mind for testing hypothetically proposed compounds before any in vitro and in vivo experimentation (Ghose, 1987; Ghose et al., 1999). |
T161 |
2807-2813 |
Sentence |
denotes |
2.2.4. |
T162 |
2815-2827 |
Sentence |
denotes |
Leadlikeness |
T163 |
2828-2986 |
Sentence |
denotes |
According to Teague et al. (1999) compounds with MW in the range 250–350, a XLOGP3 value of <3.5 and <7 rotatable bonds satisfy the criteria for leadlikeness. |
T164 |
2988-2994 |
Sentence |
denotes |
2.2.5. |
T165 |
2996-3005 |
Sentence |
denotes |
Egan rule |
T166 |
3006-3131 |
Sentence |
denotes |
It is defined as compounds having TPSA > 131.6 Å or log p > 5.88 have drug-like character and properties (Egan et al., 2000). |
T167 |
3133-3139 |
Sentence |
denotes |
2.2.6. |
T168 |
3141-3152 |
Sentence |
denotes |
Muegge rule |
T169 |
3153-3477 |
Sentence |
denotes |
It states that compounds having MW between 200 and 600, XLogP between −2 and 5, TPSA < 150, no. of rings < 7, no. of carbon atoms >4, no. of heteroatoms > 1, no. of rotatable bonds < 15, no. of H-bond acceptors < 10, no. of H-bond donors < 5 are found to obey Muegge rule and behave as potential drugs (Muegge et al., 2001). |